Triple Negative Breast Cancer: Immunogenicity, Tumor Microenvironment, and Immunotherapy

Overview

Journal Front Genet

Date 2023 Jan 30

PMID 36712858

Authors

Sotiris Loizides

Anastasia Constantinidou

Affiliations

Soon will be listed here.

Abstract

Triple negative breast cancer (TNBC) is a biologically diverse subtype of breast cancer characterized by genomic and transcriptional heterogeneity and exhibiting aggressive clinical behaviour and poor prognosis. In recent years, emphasis has been placed on the identification of mechanisms underlying the complex genomic and biological profile of TNBC, aiming to tailor treatment strategies. High immunogenicity, specific immune activation signatures, higher expression of immunosuppressive genes and higher levels of stromal Tumor Infiltrating Lymphocytes, constitute some of the key elements of the immune driven landscape associated with TNBC. The unprecedented response of TNBC to immunotherapy has undoubtedly changed the standard of care in this disease both in the early and the metastatic setting. However, the extent of interplay between immune infiltration and mutational signatures in TNBC is yet to be fully unravelled. In the present review, we present clinical evidence on the immunogenicity and tumour microenvironment influence on TNBC progression and the current treatment paradigms in TNBC based on immunotherapy.

Citing Articles

Tumor cell-derived EMP1 is essential for cancer-associated fibroblast infiltration in tumor microenvironment of triple-negative breast cancer.

Wang Q, Li D, Ma H, Li Z, Wu J, Qiao J Cell Death Dis. 2025; 16(1):143.

PMID: 40016223 PMC: 11868485. DOI: 10.1038/s41419-025-07464-9.

Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.

Serrano Garcia L, Javega B, Llombart Cussac A, Gion M, Perez-Garcia J, Cortes J Front Immunol. 2024; 15:1513421.

PMID: 39735530 PMC: 11671371. DOI: 10.3389/fimmu.2024.1513421.

Association between mammographic breast density and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.

Rella R, Belli P, Romanucci G, Bufi E, Clauser P, Masiello V Breast Cancer Res Treat. 2024; 210(1):157-166.

PMID: 39531133 DOI: 10.1007/s10549-024-07548-8.

Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer.

Shen Q, Murakami K, Sotov V, Butler M, Ohashi P, Reedijk M Sci Adv. 2024; 10(44):eado8275.

PMID: 39475614 PMC: 11524187. DOI: 10.1126/sciadv.ado8275.

Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment.

Yang Y, Li H, Yang W, Shi Y Front Immunol. 2024; 15:1441667.

PMID: 39430759 PMC: 11487198. DOI: 10.3389/fimmu.2024.1441667.

References

Szekely B, Bossuyt V, Li X, Wali V, Patwardhan G, Frederick C . Immunological differences between primary and metastatic breast cancer. Ann Oncol. 2018; 29(11):2232-2239. DOI: 10.1093/annonc/mdy399. View

Cortes J, Cescon D, Rugo H, Nowecki Z, Im S, Yusof M . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396(10265):1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. View

Jiang Y, Liu Y, Xiao Y, Hu X, Jiang L, Zuo W . Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 2020; 31(2):178-186. PMC: 8027015. DOI: 10.1038/s41422-020-0375-9. View

Brahmer J, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017; 18(12):1600-1609. DOI: 10.1016/S1470-2045(17)30690-3. View

Tarantino P, Gandini S, Trapani D, Criscitiello C, Curigliano G . Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2021; 159:103223. DOI: 10.1016/j.critrevonc.2021.103223. View

Bonsang-Kitzis H, Sadacca B, Hamy-Petit A, Moarii M, Pinheiro A, Laurent C . Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis. Oncoimmunology. 2016; 5(1):e1061176. PMC: 4760294. DOI: 10.1080/2162402X.2015.1061176. View

Anderson A, Joller N, Kuchroo V . Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity. 2016; 44(5):989-1004. PMC: 4942846. DOI: 10.1016/j.immuni.2016.05.001. View

Miller L, Chou J, Black M, Print C, Chifman J, Alistar A . Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. Cancer Immunol Res. 2016; 4(7):600-10. PMC: 4930674. DOI: 10.1158/2326-6066.CIR-15-0149. View

Garcia-Teijido P, Cabal M, Pelaez Fernandez I, Perez Y . Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clin Med Insights Oncol. 2016; 10(Suppl 1):31-9. PMC: 4822722. DOI: 10.4137/CMO.S34540. View

10.

Reisenbichler E, Han G, Bellizzi A, Bossuyt V, Brock J, Cole K . Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Mod Pathol. 2020; 33(9):1746-1752. PMC: 8366569. DOI: 10.1038/s41379-020-0544-x. View

11.

Li J, Zhang X, Zhang Z, Zheng L, Jindal S, Liu Y . Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma. Medicine (Baltimore). 2019; 98(18):e15449. PMC: 6504250. DOI: 10.1097/MD.0000000000015449. View

12.

Vollebergh M, Lips E, Nederlof P, Wessels L, Wesseling J, Vd Vijver M . Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res. 2014; 16(3):R47. PMC: 4076636. DOI: 10.1186/bcr3655. View

13.

Gomez-Macias G, Molinar-Flores G, Lopez-Garcia C, Santuario-Facio S, Decanini-Arcaute H, Valero-Elizondo J . Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization. Oncol Lett. 2020; 20(5):140. PMC: 7471657. DOI: 10.3892/ol.2020.12000. View

14.

Nanda R, Liu M, Yau C, Shatsky R, Pusztai L, Wallace A . Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020; 6(5):676-684. PMC: 7058271. DOI: 10.1001/jamaoncol.2019.6650. View

15.

Voorwerk L, Slagter M, Horlings H, Sikorska K, Van de Vijver K, de Maaker M . Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019; 25(6):920-928. DOI: 10.1038/s41591-019-0432-4. View

16.

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F . Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013; 31(7):860-7. DOI: 10.1200/JCO.2011.41.0902. View

17.

Safonov A, Jiang T, Bianchini G, Gyorffy B, Karn T, Hatzis C . Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer. Cancer Res. 2017; 77(12):3317-3324. DOI: 10.1158/0008-5472.CAN-16-3478. View

18.

Venkitaraman A . Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science. 2014; 343(6178):1470-5. DOI: 10.1126/science.1252230. View

19.

Sporikova Z, Koudelakova V, Trojanec R, Hajduch M . Genetic Markers in Triple-Negative Breast Cancer. Clin Breast Cancer. 2018; 18(5):e841-e850. DOI: 10.1016/j.clbc.2018.07.023. View

20.

Almansour N . Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front Mol Biosci. 2022; 9:836417. PMC: 8824427. DOI: 10.3389/fmolb.2022.836417. View